Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma

Cancer Letters

Volumn 306, Issue 2, 2011, Pages 161-170

  Lee, Dhong Hyun ^a,b   Thoennissen, Nils H ^a   Goff, Catherine ^a,c   Iwanski, Gabriela B ^a   Forscher, Charles ^a   Doan, Ngan B ^d   Said, Jonathan W ^d   Phillip Koeffler, H ^a,b,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Santa Monica UCLA Medical Center   (United States)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Cucurbitacin b; Methotrexate; Osteosarcoma; Synergism; Xenograft

Indexed keywords

CKBP 002; CUCURBITACIN B; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; TRITERPENOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SIZE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NONHUMAN; NUDE MOUSE; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; METHOTREXATE; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; OSTEOSARCOMA; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; TOR SERINE-THREONINE KINASES; TRITERPENES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 79955464972     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.03.001     Document Type: Article

References (41)

1. Federman N., Bernthal N., Eilber F., Tap W. The multidisciplinary management of osteosarcoma. Curr. Treat. Options Oncol. 2009, 10:82-93.
2. Rosen G., Marcove R., Caparros B., Nirenberg A., Kosloff C., Huvos A. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979, 43:2163-2177.
3. Rosen G., Caparros B., Huvos A., Kosloff C., Nirenberg A., Cacavio A., Marcove R., Lane J., Mehta B., Urban C. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982, 49:1221-1230.
4. Lee D., Iwanski G., Thoennissen N. Cucurbitacin: ancient compound shedding new light on cancer treatment. ScientificWorldJournal 2010, 10:413-418.
5. Chen J., Chiu M., Nie R., Cordell G., Qiu S. Cucurbitacins and cucurbitane glycosides: structures and biological activities. Nat. Prod. Rep. 2005, 22:386-399.
6. Nishimura R., Moriyama K., Yasukawa K., Mundy G., Yoneda T. Combination of interleukin-6 and soluble interleukin-6 receptors induces differentiation and activation of JAK-STAT and MAP kinase pathways in MG-63 human osteoblastic cells. J. Bone Miner. Res. 1998, 13:777-785.
7. E. Bogenmann, H. Moghadam, Y.A. DeClerck, A. Mock, in: c-myc Amplification and Expression in Newly Established Human Osteosarcoma Cell Lines, Cancer Research, 1987, p. 7.
8. Lomenick B., Hao R., Jonai N., Chin R., Aghajan M., Warburton S., Wang J., Wu R., Gomez F., Loo J., Wohlschlegel J., Vondriska T., Pelletier J., Herschman H., Clardy J., Clarke C., Huang J. Target identification using drug affinity responsive target stability (DARTS). Proc. Natl. Acad. Sci. USA 2009, 106:21984-21989.
9. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008, 22:659-661.
10. Luong Q., O'Kelly J., Braunstein G., Hershman J., Koeffler H. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin. Cancer Res. 2006, 12:5570-5577.
11. Abramoff M.D.M., Ram P.J. Image processing with image. J. Biophotonics Int. 2004, 11:7.
12. Iwanski G., Lee D., En-Gal S., Doan N., Castor B., Vogt M., Toh M., Bokemeyer C., Said J., Thoennissen N., Koeffler H. Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. Br. J. Pharmacol. 2010, 160:998-1007.
13. Chou T., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
14. Chou T. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70:440-446.
15. T.C. Chou, M.P. Hayball, CalcuSyn Sofrware, Version 2.0, Biosoft, Cambridge, UK, 1997.
16. Pouysségur J., Dayan F., Mazure N. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441:437-443.
17. Mariani B., Slate D., Schimke R. S phase-specific synthesis of dihydrofolate reductase in Chinese hamster ovary cells. Proc. Natl. Acad. Sci. USA 1981, 78:4985-4989.
18. Gorlick R., Goker E., Trippett T., Waltham M., Banerjee D., Bertino J. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl. J. Med. 1996, 335:1041-1048.
19. Lobo E., Balthasar J. Pharmacokinetic-pharmacodynamic modeling of methotrexate-induced toxicity in mice. J. Pharm. Sci. 2003, 92:1654-1664.
20. Margolis S., Philips F., Sternberg S. The cytotoxicity of methotrexate in mouse small intestine in relation to inhibition of folic acid reductase and of DNA synthesis. Cancer Res. 1971, 31:2037-2046.
21. Forbes S.A., Tang G., Bindal N., Bamford S., Dawson E., Cole C., Kok C.Y., Jia M., Ewing R., Menzies A., Teague J.W., Stratton M.R., Futreal P.A. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 2010, 38:D652-657.
22. Do S., Jung W., Kim H., Park Y. The expression of epidermal growth factor receptor and its downstream signaling molecules in osteosarcoma. Int. J. Oncol. 2009, 34:797-803.
23. Freeman S.S., Allen S.W., Ganti R., Wu J., Ma J., Su X., Neale G., Dome J.S., Daw N.C., Khoury J.D. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer 2008, 113:1453-1461.
24. Zhang W., Lee J.C., Kumar S., Gowen M. ERK pathway mediates the activation of Cdk2 in IGF-1-induced proliferation of human osteosarcoma MG-63 cells. J. Bone Miner. Res. 1999, 14:528-535.
25. Burrow S., Andrulis I.L., Pollak M., Bell R.S. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J. Surg. Oncol. 1998, 69:21-27.
26. Coltella N., Manara M.C., Cerisano V., Trusolino L., Di Renzo M.F., Scotlandi K., Ferracini R. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB J. 2003, 17:1162-1164.
27. Heldin C.H., Johnsson A., Wennergren S., Wernstedt C., Betsholtz C., Westermark B. A human osteosarcoma cell line secretes a growth factor structurally related to a homodimer of PDGF A-chains. Nature 1986, 319:511-514.
28. Graves D.T., Owen A.J., Antoniades H.N. Demonstration of receptors for a PDGF-like mitogen on human osteosarcoma cells. Biochem. Biophys. Res. Commun. 1985, 129:56-62.
29. Abdeen A., Chou A., Healey J., Khanna C., Osborne T., Hewitt S., Kim M., Wang D., Moody K., Gorlick R. Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. Cancer 2009, 115:5243-5250.
30. Zhang W., Dziak R., Aletta J. EGF-mediated phosphorylation of extracellular signal-regulated kinases in osteoblastic cells. J. Cell Physiol. 1995, 162:348-358.
31. Kiyokawa E., Takai S., Tanaka M., Iwase T., Suzuki M., Xiang Y., Naito Y., Yamada K., Sugimura H., Kino I. Overexpression of ERK, an EPH family receptor protein tyrosine kinase, in various human tumors. Cancer Res. 1994, 54:3645-3650.
32. Zhang Z., Neiva K., Lingen M., Ellis L., Nör J. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ. 2010, 17:499-512.
33. Chan K., Li K., Liu S., Chu K., Toh M., Xie W. Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562. Cancer Lett. 2010, 289:46-52.
34. Feldman M., Apsel B., Uotila A., Loewith R., Knight Z., Ruggero D., Shokat K. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009, 7:e38.
35. Diddens H., Niethammer D., Jackson R. Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate. Cancer Res. 1983, 43:5286-5292.
36. Teachey D., Sheen C., Hall J., Ryan T., Brown V., Fish J., Reid G., Seif A., Norris R., Chang Y., Carroll M., Grupp S. mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood 2008, 112:2020-2023.
37. Müller H., Lukas J., Schneider A., Warthoe P., Bartek J., Eilers M., Strauss M. Cyclin D1 expression is regulated by the retinoblastoma protein. Proc. Natl. Acad. Sci. USA 1994, 91:2945-2949.
38. Serra M., Reverter-Branchat G., Maurici D., Benini S., Shen J., Chano T., Hattinger C., Manara M., Pasello M., Scotlandi K., Picci P. Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Ann. Oncol. 2004, 15:151-160.
39. Bruheim S., Bruland O., Breistol K., Maelandsmo G., Fodstad O. Human osteosarcoma xenografts and their sensitivity to chemotherapy. Pathol. Oncol. Res. 2004, 10:133-141.
40. Guertin D., Sabatini D. The pharmacology of mTOR inhibition. Sci. Signal. 2009, 2:pe24.
41. Gazitt Y., Kolaparthi V., Moncada K., Thomas C., Freeman J. Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways. Int. J. Oncol. 2009, 34:551-561.